Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

Google Scholar 

Wu S, Zhu W, Thompson P, Hannun YA. Evaluating intrinsic and non-intrinsic cancer risk factors. Nat Commun. 2018;9(1):3490.

Google Scholar 

Klein AP. Pancreatic cancer epidemiology: Understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493–502.

Google Scholar 

Cheng Y, Zhang T, Xu Q. Therapeutic advances in non-small cell lung cancer: focus on clinical development of targeted therapy and immunotherapy. MedComm (2020). 2021;2(4):692–729.

Google Scholar 

Chi H, Gao X, Xia Z, Yu W, Yin X, Pan Y, Peng G, Mao X, Teichmann AT, Zhang J, Tran LJ, Jiang T, Liu Y, Yang G, Wang Q. FAM family gene prediction model reveals heterogeneity, stemness and immune microenvironment of UCEC. Front Mol Biosci. 2023;10:1200335.

CAS  Google Scholar 

Liang S, Liu Y, He J, Gao T, Li L, He S. Family with sequence similarity 46 member a confers chemo-resistance to ovarian carcinoma via TGF-β/Smad2 signaling. Bioengineered. 2022;13(4):10629–39.

CAS  Google Scholar 

Ren D, Zhuang X, Lv Y, Zhang Y, Xu J, Gao F, Chen D, Wang Y. Identification of family with sequence similarity 110 member C (FAM110C) as a candidate diagnostic and prognostic biomarker for glioma. Iran J Public Health. 2023;52(10):2117–27.

Google Scholar 

Schabath MB, Cote ML. Cancer progress and priorities: lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563–79.

Google Scholar 

Ramos-Paradas J, Gómez-Sánchez D, Rosado A, Ucero AC, Ferrer I, García-Luján R, Zugazagoitia J, Carrizo N, Enguita AB, Conde E, Garrido-Martin EM, Paz-Ares L. Comprehensive characterization of human lung large cell carcinoma identifies transcriptomic signatures with potential implications in response to immunotherapy. J Clin Med. 2022;11(6):1500.

Herrera-Juárez M, Serrano-Gómez C, Bote-De-Cabo H, Paz-Ares L. Targeted therapy for lung cancer: beyond EGFR and ALK. Cancer. 2023;129(12):1803–20.

Google Scholar 

Wu F, Wang L, Zhou C. Lung cancer in china: current and prospect. Curr Opin Oncol. 2021;33(1):40–6.

CAS  Google Scholar 

Bozatzi P, Sapkota GP. The FAM83 family of proteins: from pseudo-PLDs to anchors for CK1 isoforms. Biochem Soc Trans. 2018;46(3):761–71.

CAS  Google Scholar 

Zhang J, Sun G, Mei X. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma. Cancer Biomark. 2019;26(3):367–73.

CAS  Google Scholar 

Zhang JT, Lin YC, Xiao BF, Yu BT. Overexpression of family with sequence similarity 83, member A (FAM83A) predicts poor clinical outcomes in lung adenocarcinoma. Med Sci Monit. 2019;25:4264–72.

Google Scholar 

Wang C, Zhang J, Wang H, Chen R, Lu M. Family with sequence similarity 83, member A (FAM83A) inhibits ferroptosis via the Wnt/β-catenin pathway in lung squamous cell cancer. Cell Death Discov. 2024;10(1):332.

CAS  Google Scholar 

Yuan Y, Hao L, Huang JS, Zhao FY, Ju YH, Wang JM, Zhang T, Li BQ, Yu ZW. Promotion of stem cell-like phenotype of lung adenocarcinoma by FAM83A via stabilization of ErbB2. Cell Death Dis. 2024;15(6):460.

Google Scholar 

Wang T, Zhu X, Wang K. CircMIIP contributes to Non-Small cell lung Cancer progression by binding miR-766-5p to upregulate FAM83A expression. Lung. 2022;200(1):107–17.

CAS  Google Scholar 

Ning Z, Tian Y, Li Y, Zhao X, Zhang J, Wang C, Hu J, Shen H, Wu W. Exosomal circ_0007385 enhances non-small cell lung cancer cell proliferation and stemness via regulating miR-1253/FAM83A axis. Anticancer Drugs. 2022;33(1):61–74.

CAS  Google Scholar 

Zheng YW, Li ZH, Lei L, Liu CC, Wang Z, Fei LR, Yang MQ, Huang WJ, Xu HT. FAM83A promotes lung Cancer progression by regulating the Wnt and Hippo signaling pathways and indicates poor prognosis. Front Oncol. 2020;10:180.

Google Scholar 

Yuan W, Liu W, Huang H, Chen X, Zhang R, Lyu H, Xiao S, Guo D, Zhang Q, Ali DW, Michalak M, Chen XZ, Zhou C, Tang J. Screening and identification of MiRNAs negatively regulating FAM83A/Wnt/β-catenin signaling pathway in non-small cell lung cancer. Sci Rep. 2024;14(1):17394.

CAS  Google Scholar 

Hu H, Wang F, Wang M, Liu Y, Wu H, Chen X, Lin Q. FAM83A is amplified and promotes tumorigenicity in non-small cell lung cancer via ERK and PI3K/Akt/mTOR pathways. Int J Med Sci. 2020;17(6):807–14.

CAS  Google Scholar 

Zhou F, Geng J, Xu S, Meng Q, Chen K, Liu F, Yang F, Pan B, Yu Y. FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC. Aging. 2019;11(16):6069–88.

CAS  Google Scholar 

Okabe N, Ezaki J, Yamaura T, Muto S, Osugi J, Tamura H, Imai J, Ito E, Yanagisawa Y, Honma R, Gotoh M, Watanabe S, Waguri S, Suzuki H. FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma. Int J Oncol. 2015;46(3):999–1006.

CAS  Google Scholar 

Yamaura T, Ezaki J, Okabe N, Takagi H, Ozaki Y, Inoue T, Watanabe Y, Fukuhara M, Muto S, Matsumura Y, Hasegawa T, Hoshino M, Osugi J, Shio Y, Waguri S, Tamura H, Imai JI, Ito E, Yanagisawa Y, Honma R, Watanabe S, Suzuki H. Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor. Oncol Lett. 2018;15(2):1549–58.

Google Scholar 

Zhang J, Wang J, Yue K, Li P, Shen W, Qiao X, Wang Y, Wu X. FAM83B promotes the invasion of primary lung adenocarcinoma via PI3K/AKT/NF-κB pathway. BMC Pulm Med. 2023;23(1):32.

Google Scholar 

Zhao T, Wang M, Zhao X, Weng S, Qian K, Shi K, Gu Y, Ying W, Qian X, Zhang Y. YTHDF2 inhibits the migration and invasion of lung adenocarcinoma by negatively regulating the FAM83D-TGFβ1-SMAD2/3 pathway. Front Oncol. 2022;12:763341.

CAS  Google Scholar 

Yu C, Cheng Z, Cui S, Mao X, Li B, Fu Y, Wang H, Jin H, Ye Q, Zhao X, Jiang L, Qin W. circFOXM1 promotes proliferation of non-small cell lung carcinoma cells by acting as a CeRNA to upregulate FAM83D. J Exp Clin Cancer Res. 2020;39(1):55.

CAS  Google Scholar 

Tai G, Zhang M, Liu F. Circ_0000735 enhances the proliferation, metastasis and Glycolysis of non-small cell lung cancer by regulating the miR-635/FAM83F axis. Exp Lung Res. 2021;47(3):136–48.

CAS  Google Scholar 

Gu GM, Zhan YY, Abuduwaili K, Wang XL, Li XQ, Zhu HG, Liu CL. MiR-940 inhibits the progression of NSCLC by targeting FAM83F. Eur Rev Med Pharmacol Sci. 2018;22(18):5964–71.

Google Scholar 

Fan G, Xu P, Tu P. MiR-1827 functions as a tumor suppressor in lung adenocarcinoma by targeting MYC and FAM83F. J Cell Biochem. 2020;121(2):1675–89.

CAS  Google Scholar 

Eisenhut F, Heim L, Trump S, Mittler S, Sopel N, Andreev K, Ferrazzi F, Ekici AB, Rieker R, Springel R, Assmann VL, Lechmann M, Koch S, Engelhardt M, Warnecke C, Trufa DI, Sirbu H, Hartmann A, Finotto S. FAM13A is associated with non-small cell lung cancer (NSCLC) progression and controls tumor cell proliferation and survival. Oncoimmunology. 2017;6(1):e1256526.

Google Scholar 

Hou Q, Jiang Z, Li Y, Wu H, Yu J, Jiang M. FAM60A promotes cisplatin resistance in lung cancer cells by activating SKP2 expression. Anticancer Drugs. 2020;31(8):776–84.

CAS  Google Scholar 

Chen F, Ren P, Xu R, Zhang J, Liang C, Qiang G. FAM65A promotes the progression and growth of lung squamous cell carcinoma in vivo and vitro. BMC Cancer. 2024;24(1):944.

CAS  Google Scholar 

Kawasaki K, Nojima S, Hijiki S, Tahara S, Ohshima K, Matsui T, Hori Y, Kurashige M, Umeda D, Kiyokawa H, Kido K, Okuzaki D, Morii E. FAM111B enhances proliferation of KRAS-driven lung adenocarcinoma by degrading p16. Cancer Sci. 2020;111(7):2635–46.

CAS  Google Scholar 

Tomioka Y, Seki N, Suetsugu T, Hagihara Y, Sanada H, Goto Y, Kikkawa N, Mizuno K, Tanaka K, Inoue H. Identification of tumor suppressive miR-144-5p targets: FAM111B expression accelerates the malignant phenotypes of lung adenocarcinoma. Int J Mol Sci. 2024;25(18):9974.

Zhang N, Zhou XM, Yang FF, Zhang Q, Miao Y, Hou G. FAM129A promotes invasion and proliferation by activating FAK signaling pathway in non-small cell lung cancer. Int J Clin Exp Pathol. 2019;12(3):893–900.

CAS  Google Scholar 

Zhou X, Yang F, Zhang Q, Miao Y, Hu X, Li A, Hou G, Wang Q, Kang J. FAM129B promoted tumor invasion and proliferation via facilitating the phosphorylation of FAK signaling and associated with adverse clinical outcome of non-small cell lung cancer patients. Onco Targets Ther. 2018;11:7493–501.

CAS  Google Scholar 

Zhao L, Ge C, Zhang Z, Hu H, Zhang Y, Zhao W, Li R, Zeng B, Song X, Li G. FAM136A immunoreactivity is associated with nodal involvement and survival in lung adenocarcinoma in a Chinese case series. Bioengineered. 2020;11(1):261–71.

CAS  Google Scholar 

Jang EJ, Sung JY, Yoo HE, Jang H, Shim J, Oh ES, Goh SH, Kim YN. FAM188B downregulation sensitizes lung Cancer cells to Anoikis via EGFR downregulation and inhibits tumor metastasis in vivo. Cancers (Basel). 2021;13(2):247.

Choi YE, Madhi H, Kim H, Lee JS, Kim MH, Kim YN, Goh SH. FAM188B expression is critical for cell growth via FOXM1 regulation in lung Cancer. Biomedicines 2020;8(11):465.

Huang J, Yu Q, Zhou Y, Chu Y, Jiang F, Wang Q. FAM201A knockdown inhibits proliferation and invasion of lung adenocarcinoma cells by regulating miR-7515/GLO1 axis. J Cell Physiol. 2021;236(8):5620–32.

CAS  Google Scholar 

Xie M, Cai L, Li J, Zhao J, Guo Y, Hou Z, Zhang X, Tian H, Li A, Miao Y. FAM110B inhibits Non-Small cell lung Cancer cell proliferation and invasion through inactivating Wnt/β-Catenin signaling. Onco Targets Ther. 2020;13:4373–84.

CAS  Google Scholar 

Xie H, Hu J, Pan H, Lou Y, Lv P, Chen Y. Adenovirus vector-mediated FAM176A overexpression induces cell death in human H1299 non-small cell lung cancer cells. BMB Rep. 2014;47(2):104–9.

Google Scholar 

Liu J, Zhao W, Luan Y, Tian Z. FAM189A2 plays a tumour suppressor role in lung adenocarcinoma by influencing cell apoptosis, CXCR4 expression and tight junction proteins. Tissue Cell. 2024;89:102441.

CAS  Google Scholar 

Hsu CY, Chang GC, Chen YJ, Hsu YC, Hsiao YJ, Su KY, Chen HY, Lin CY, Chen JS, Chen YJ, Hong QS, Ku WH, Wu CY, Ho BC, Chiang CC, Yang PC, Yu SL. FAM198B is associated with prolonged survival and inhibits metastasis in lung adenocarcinoma via blockage of ERK-Mediated MMP-1 expression. Clin Cancer Res. 2018;24(4):916–26.

CAS  Google Scholar 

Gong Y, Ji P, Yang YS, Xie S, Yu TJ, Xiao Y, Jin ML, Ma D, Guo LW, Pei YC, Chai WJ, Li DQ, Bai F, Bertucci F, Hu X, Jiang YZ, Shao ZM. Metabolic-Pathway-Based subtyping of Triple-Negative breast Cancer reveals potential therapeutic targets. Cell Metab. 2021;33(1):51–e6459.

CAS  Google Scholar 

Xu R, Tan H, Zhang J, Yuan Z, Xie Q, Zhang L. Fam20C in human diseases: emerging biological functions and therapeutic implications. Front Mol Biosci. 2021;8:790172.

CAS  Google Scholar 

Tagliabracci VS, Wiley SE, Guo X, Kinch LN, Durrant E, Wen J, Xiao J, Cui J, Nguyen KB, Engel JL, Coon JJ, Grishin N, Pinna LA, Pagliarini DJ, Dixon JE. A single kinase generates the majority of the secreted phosphoproteome. Cell. 2015;161(7):1619–32.

CAS  Google Scholar 

Zhao R, Fu L, Yuan Z, Liu Y, Zhang K, Chen Y, Wang L, Sun D, Chen L, Liu B, Zhang L. Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer. Eur J Med Chem. 2021;210:113088.

CAS  Google Scholar 

Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–7.